This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nakakita Yakuhin Co., ltd. acquired Yakuhan Pharmaceutical Co., Ltd. from Nichi-Iko Pharmaceutical Co., Ltd. CI
Nichi-Iko Pharmaceutical Co., Ltd.(TSE:4541) dropped from S&P Global BMI Index CI
Japan Shares End Flat on Last Trading Day of 2022; Nichi-Iko Pharmaceutical Shares Plummet 24% MT
Nichi-Iko Pharmaceutical Secures 98.5 Billion Yen of Debt Relief, Plans 20 Billion Yen Share Allotment; Shares Plunge 20% MT
Nichi-Iko Pharmaceutical More Than Triples Fiscal H1 Profit MT
Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive Ñ19.998404811 billion in funding from Godo Kaisha JSD CI
Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pandemic Level MT
Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Nichi-iko Pharmaceutical MT
Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko MT
Nichi-Iko Pharmaceutical's Nine-Month Profit Soars MT
Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022 CI
Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko and Nissan Chemical MT
Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2021 CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in funding from MediPal Holdings Corporation CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billion in funding from MediPal Holdings Corporation CI
Fuji Chemical Industries Co., Ltd. agreed to acquire Toyama No. 2 Factory of Nichi-Iko in Namerikawa City, Toyama Prefecture from Nichi-Iko Pharmaceutical Co., Ltd.. CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year-End of Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Year Ended March 31, 2021 CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2021, Payable on June 21, 2021; Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2022 CI
Nichi-Iko Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022 CI
Chart Nichi-Iko Pharmaceutical Co., Ltd.
More charts
Nichi-Iko Pharmaceutical Co.,Ltd. is a Japan-based company principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed.
More about the company
  1. Stock Market
  2. Equities
  3. 4541 Stock
  4. News Nichi-Iko Pharmaceutical Co., Ltd.
  5. Nichi-Iko Pharmaceutical More Than Triples Fiscal H1 Profit